{"id":2402,"date":"2026-10-05T13:51:32","date_gmt":"2026-10-05T08:21:32","guid":{"rendered":"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-10-05\/"},"modified":"2026-10-05T20:15:54","modified_gmt":"2026-10-05T14:45:54","slug":"mankind-share-price-today-2026-10-05","status":"publish","type":"post","link":"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-10-05\/","title":{"rendered":"Why Mankind Pharma Shares Fell 2.21% Today: Sector Weakness &#038; Context | 5 October 2026"},"content":{"rendered":"<style id=\"wt-article-style-v4\">:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) { color:#30475c; font-size:16px; line-height:1.65; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::before, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) *::after { box-sizing:border-box; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-copy { font-size:16px !important; line-height:1.65 !important; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-prose .wt-copy { margin-bottom:15px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-market-date { font-size:13px !important; line-height:1.55; color:#566b80; background:#f2f6f9; border:1px solid #dde6ec; border-left:4px solid #2e7db2; border-radius:6px; padding:8px 11px; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { display:grid; grid-template-columns:repeat(6,minmax(0,1fr)); gap:7px; margin:8px 0 16px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:10px !important; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:first-child { font-size:11px !important; line-height:1.45; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child { font-size:14px !important; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px 16px; min-width:0; overflow-wrap:anywhere; margin:14px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-title { font-size:16px; font-weight:800; line-height:1.45; color:#17324d; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-date { font-size:13px; line-height:1.5; color:#566b80; margin-bottom:9px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body { font-size:16px; line-height:1.6; color:#34495d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card-body .wt-copy:last-child { margin-bottom:0 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { display:grid; grid-template-columns:repeat(2,minmax(0,1fr)); gap:12px; margin:12px 0 18px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > .wt-card { margin:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid > :only-child { grid-column:1 \/ -1; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(3,minmax(0,1fr)); margin:10px 0 12px; gap:10px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-metric { background:#fff; border:1px solid #e1e8ef; border-radius:8px; padding:10px 12px; min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-label { display:block; font-size:12px; font-weight:700; color:#566b80; line-height:1.5; margin-bottom:3px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-value { font-size:18px; font-weight:800; line-height:1.45; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-note { display:block; font-size:13px; color:#566b80; line-height:1.55; margin-top:4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source-note { margin:9px 0 4px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-source { display:inline-block; font-size:13px; line-height:1.5; margin-top:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { display:grid; grid-template-columns:2fr 1fr 1.2fr 1.2fr; gap:14px; padding:12px 0; border-bottom:1px solid #c9dbef; align-items:start; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row:last-of-type { border-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row strong { font-size:15px; line-height:1.5; display:block; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div { min-width:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds { grid-template-columns:repeat(3,minmax(0,1fr)); margin:12px 0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card { padding:12px; background:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title { font-size:14px; font-weight:700; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:14px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-brokerage { grid-template-columns:1fr; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts { display:flex; flex-wrap:wrap; gap:14px 28px; margin:7px 0 12px; padding-bottom:10px; border-bottom:1px solid #cbd8ea; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-broker-facts strong { font-size:16px; color:#17324d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list { font-size:16px !important; line-height:1.65; margin:0 0 12px; padding-left:20px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-list li { margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card { background:#f7fbff !important; border-color:#cfe1f2 !important; border-left-color:#2e7db2 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-card-title { color:#1f4d70; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-takeaways .wt-list { margin-bottom:0; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card { background:#f5fbfd !important; border-color:#c9d9e7 !important; border-left:5px solid #1f7b92 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-title { color:#174c5d; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-likely-reason .wt-card-body > strong { display:block; margin-bottom:6px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:18px 19px; margin:22px 0; border-radius:13px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:19px; font-weight:800; line-height:1.4; margin-bottom:7px; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow { background:linear-gradient(135deg,#ffe873,#ffd64a); border:1px solid #e3b600; box-shadow:0 8px 18px rgba(59,48,0,.09); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-title { color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-yellow .wt-cta-copy { color:#27364b !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark { background:#10233f; box-shadow:0 9px 22px rgba(16,35,63,.18); }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-title { color:#fff !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-copy { color:#dce6f1 !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-copy { font-size:16px !important; line-height:1.6; margin:0 0 12px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-button { display:inline-block; background:#10233f; color:#fff !important; padding:10px 17px; border-radius:7px; text-decoration:none !important; font-size:15px; font-weight:800; line-height:1.5; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-dark .wt-cta-button { background:#ffe36e; color:#10233f !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-faq h3 { color:#173b58 !important; font-size:17px !important; line-height:1.45; margin:18px 0 6px !important; }\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) > p:last-child { font-size:13px; line-height:1.55; color:#606b78; border-top:1px solid #e1e7ef; padding-top:13px; margin-top:16px; }\n@media (max-width:960px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(3,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:1.7fr 1fr 1.2fr 1.2fr; gap:10px; }\n}\n@media (max-width:650px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid { grid-template-columns:1fr; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-metrics { grid-template-columns:repeat(2,minmax(0,1fr)); }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-card { padding:14px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row { grid-template-columns:repeat(2,minmax(0,1fr)); gap:10px 14px; padding:12px 0; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-person, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-insider-row > div:last-child { grid-column:1 \/ -1; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta { padding:17px 15px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-cta-title { font-size:18px; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div { padding:9px !important; }\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-title, :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-grid-funds .wt-card-body { font-size:15px; }\n}\n@media (max-width:420px) {\n :is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip { grid-template-columns:repeat(2,minmax(0,1fr)); }\n}<\/p>\n<p>:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div {border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) .wt-price-strip > div > div:last-child {font-weight:800;color:#17324d;}\n:is(.wt-article-v4,.single-post .entry-content .wt-article-v4) h2 {font-size:24px !important;line-height:1.35 !important;margin:28px 0 14px !important;color:#173b58;}\n<\/style>\n<div data-approved-layout=\"1061-v1\" class=\"wt-article-v4\" data-article-version=\"4\">\n<p class=\"wt-market-date\"><strong>NSE: MANKIND<\/strong> \u00b7 5 October 2026 \u00b7 Dated market coverage<\/p>\n<div style=\"flex-wrap:wrap;gap:7px;margin:8px 0 14px;\" class=\"wt-price-strip\">\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Price<\/div>\n<div style=\"font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">\u20b92,479.00<\/div>\n<\/p><\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Change<\/div>\n<div style=\"font-weight:900;color:#b42318;margin-top:2px;overflow-wrap:anywhere;\">-2.21%<\/div>\n<\/p><\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">High \/ Low<\/div>\n<div style=\"font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">\u20b92,535.60 \/ \u20b92,464.90<\/div>\n<\/p><\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Prev. Close<\/div>\n<div style=\"font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">\u20b92,535.00<\/div>\n<\/p><\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Volume<\/div>\n<div style=\"font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">5.17L<\/div>\n<\/p><\/div>\n<div style=\"flex:1 1 98px;min-width:0;border:1px solid #dde6ee;border-radius:8px;background:#f9fbfd;padding:8px 9px;box-sizing:border-box;\">\n<div style=\"text-transform:uppercase;letter-spacing:.3px;color:#758392;font-weight:800;\">Updated<\/div>\n<div style=\"font-weight:900;color:#17324d;margin-top:2px;overflow-wrap:anywhere;\">03:10 PM<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<div style=\"background:#f7fbff;border:1px solid #cfe1f2;border-left:4px solid #2e7db2;border-radius:10px;padding:13px 15px;margin:12px 0 18px;\" class=\"wt-card\">\n<div style=\"font-weight:900;color:#1f4d70;margin-bottom:6px;\" class=\"wt-card-title\">Key Takeaways<\/div>\n<ul style=\"margin:0;padding-left:18px;\">\n<li>MANKIND PHARMA LIMITED was trading<strong>2.21% lower<\/strong>at \u20b92,479.00 and near the lower end of the day&#8217;s trading range. <\/li>\n<li><strong>Likely reason:<\/strong>sector-aligned profit booking and subdued volume. <\/li>\n<li>Cash volume was around<strong>93% of the 20-day average full-session volume<\/strong>, so participation remained below an average full session. <\/li>\n<\/ul><\/div>\n<h2>Why Mankind Pharma Shares Are Falling 2.21% Today<\/h2>\n<div class=\"wt-prose\">\n<p class=\"wt-copy\">Mankind Pharma Limited shares declined 2.21% during the session, settling at \u20b92,479.0 after opening at \u20b92,531.60. The stock traded within a relatively narrow intraday band between a high of \u20b92,535.60 and a low of \u20b92,464.90, failing to hold its previous close of \u20b92,535.0. Trading activity remained subdued, with total volume reaching 516,909 shares, representing about 56% of its 5-day average volume.<\/p>\n<p class=\"wt-copy\">The broader market showed positive momentum as the Nifty benchmark advanced 0.6%, whereas pharmaceutical equities faced selling pressure, with the Nifty Pharma sector index slipping 0.74%. Mankind Pharma underperformed both the wider market and its immediate sector peers, reflecting mild corrective pullbacks despite its recent 20-day return of 6.49%.<\/p>\n<p class=\"wt-copy\">On the corporate front, recent regulatory filings highlighted administrative updates, including the resignation of statutory auditors at its material wholly-owned subsidiary, Bharat Serums and Vaccines Limited, alongside ongoing steps for its voluntary liquidation. Additionally, the company recently announced an exclusive in-licensing agreement for Insulin Degludec and Insulin Degludec plus Aspart combinations for the Indian market, though these structural developments serve as backdrop context rather than direct catalysts for today&#8217;s intraday price adjustment.<\/p>\n<\/div>\n<div style=\"border:1px solid #c9d9e7;border-left:5px solid #1f7b92;border-radius:10px;background:#f5fbfd;padding:14px 16px;margin:15px 0 20px;\" class=\"wt-card\">\n<div style=\"font-weight:900;color:#174c5d;margin-bottom:6px;\" class=\"wt-card-title\">Likely Reason for Today&#8217;s Move<\/div>\n<div style=\"font-weight:850;color:#20384a;margin-bottom:6px;\">sector-aligned profit booking and subdued volume<\/div>\n<div style=\"\">The downward move appears largely driven by sector-wide weakness in pharmaceutical stocks coupled with routine profit-taking following recent gains. No single major negative corporate catalyst emerged during the session to justify the decline.<\/div>\n<ul style=\"margin:8px 0 0;padding-left:18px;\">\n<li>Nifty Pharma sector index fell 0.74% while broader markets rose.<\/li>\n<li>Trading volume was thin at 56% of the 5-day average.<\/li>\n<li>The stock recently posted a 20-day return of 6.49%, leaving it susceptible to mild corrective pullbacks.<\/li>\n<\/ul><\/div>\n<aside class=\"wt-cta wt-cta-yellow\">\n<div class=\"wt-cta-title\">Research the Market \u2014 Not Just the Headline<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Latest Company Developments<\/h2>\n<div style=\"gap:10px;margin:10px 0 22px;\" class=\"wt-card\">\n<div style=\"border:1px solid #dce5eb;border-radius:10px;padding:13px 14px;background:#fff;min-width:0;\">\n<div style=\"font-weight:900;color:#17324d;\">Resignation of Subsidiary Statutory Auditors<\/div>\n<div style=\"color:#708090;margin:3px 0 6px;\">28-Sep-2026<\/div>\n<div style=\"color:#34495d;\">Mankind Pharma informed exchanges regarding the resignation of statutory auditors at its material wholly-owned subsidiary, Bharat Serums and Vaccines Limited. The filing outlines routine corporate compliance disclosures regarding changes in subsidiary audit oversight.<\/div>\n<\/p><\/div>\n<div style=\"border:1px solid #dce5eb;border-radius:10px;padding:13px 14px;background:#fff;min-width:0;\">\n<div style=\"font-weight:900;color:#17324d;\">Update on Voluntary Liquidation of Subsidiary<\/div>\n<div style=\"color:#708090;margin:3px 0 6px;\">07-Sep-2026<\/div>\n<div style=\"color:#34495d;\">The company provided ongoing updates regarding the voluntary liquidation and corporate integration of its wholly-owned material subsidiary, Bharat Serums and Vaccines Limited. This follows earlier board consents obtained to streamline group structures.<\/div>\n<\/p><\/div>\n<div style=\"border:1px solid #dce5eb;border-radius:10px;padding:13px 14px;background:#fff;min-width:0;\">\n<div style=\"font-weight:900;color:#17324d;\">Exclusive In-Licensing Agreement for Insulin Products<\/div>\n<div style=\"color:#708090;margin:3px 0 6px;\">20-Aug-2026<\/div>\n<div style=\"color:#34495d;\">Mankind Pharma entered into an exclusive in-licensing agreement to commercialize Insulin Degludec and Insulin Degludec plus Aspart combination products in India. The strategic tie-up strengthens the company&#8217;s anti-diabetic and chronic care product portfolio.<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<h2>Ownership &amp; Transaction Activity<\/h2>\n<div style=\"gap:12px;margin:11px 0 22px;\">\n<div style=\"background:#fff8e8;border:1px solid #ecd39e;border-left:5px solid #cc922c;border-radius:10px;padding:14px 15px;min-width:0;\" class=\"wt-card\">\n<div style=\"font-weight:900;color:#8c6318;margin-bottom:9px;\" class=\"wt-card-title\">Promoter Pledge \/ Encumbrance<\/div>\n<div style=\"gap:7px;\">\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"text-transform:uppercase;color:#74808d;font-weight:800;\">Promoter Holding<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:3px;\">72.63%<\/div>\n<div style=\"color:#71808d;margin-top:2px;\">72.66% previous qtr<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<div style=\"background:#f5f8fb;border:1px solid #d5e0ea;border-left:5px solid #6a849c;border-radius:10px;padding:14px 15px;min-width:0;\" class=\"wt-card\">\n<div style=\"font-weight:900;color:#405d76;margin-bottom:9px;\" class=\"wt-card-title\">Recent Ownership \/ Shareholding<\/div>\n<div style=\"gap:7px;\">\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"text-transform:uppercase;color:#74808d;font-weight:800;\">FII\/FPI<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:3px;\">9.45%<\/div>\n<div style=\"color:#71808d;margin-top:2px;\">10.24% previous qtr<\/div>\n<\/p><\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"text-transform:uppercase;color:#74808d;font-weight:800;\">Mutual Funds<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:3px;\">10.87%<\/div>\n<div style=\"color:#71808d;margin-top:2px;\">10.36% previous qtr<\/div>\n<\/p><\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"text-transform:uppercase;color:#74808d;font-weight:800;\">Institutional<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:3px;\">24.84%<\/div>\n<div style=\"color:#71808d;margin-top:2px;\">24.70% previous qtr<\/div>\n<\/p><\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:8px;padding:9px 10px;min-width:0;\">\n<div style=\"text-transform:uppercase;color:#74808d;font-weight:800;\">MF Schemes<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:3px;\">36<\/div>\n<div style=\"color:#71808d;margin-top:2px;\">31 previous qtr<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<h2>Mutual Fund Holdings<\/h2>\n<div style=\"border:1px solid #d5e0ea;border-radius:11px;background:#f7f9fc;padding:14px 15px;margin:10px 0 22px;\" class=\"wt-card\">\n<div style=\"color:#34495d;margin-bottom:10px;\">Mutual funds increased their aggregate stake to<strong>10.87%<\/strong>from <strong>10.36%<\/strong>in the previous quarter. The number of disclosed MF\/UTI shareholders was 36, versus 31 in the previous quarter. <\/div>\n<div style=\"gap:8px;\">\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:9px;padding:10px 11px;min-width:0;\">\n<div style=\"font-weight:850;color:#20384a;\">NIPPON LIFE INDIA TRUSTEE LTD-A\/C NIPPON INDIA NIF<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:4px;\">8.55M shares \u2022 2.07%<\/div>\n<div style=\"color:#74808d;margin-top:2px;\">30-JUN-2026<\/div>\n<\/p><\/div>\n<div style=\"background:#fff;border:1px solid #e1e8ef;border-radius:9px;padding:10px 11px;min-width:0;\">\n<div style=\"font-weight:850;color:#20384a;\">SBI ARBITRAGE OPPORTUNITIES FUND<\/div>\n<div style=\"font-weight:950;color:#17324d;margin-top:4px;\">6.43M shares \u2022 1.56%<\/div>\n<div style=\"color:#74808d;margin-top:2px;\">30-JUN-2026<\/div>\n<\/p><\/div>\n<\/p><\/div>\n<\/p><\/div>\n<h2>What to Watch Next<\/h2>\n<ul style=\"\">\n<li>Subsidiary restructuring and integration progress for Bharat Serums and Vaccines Limited<\/li>\n<li>Execution and commercialization timelines for the newly in-licensed insulin products<\/li>\n<li>Delivery percentage trends relative to the 53.59% recorded in the recent session<\/li>\n<\/ul>\n<aside class=\"wt-cta wt-cta-dark\">\n<div class=\"wt-cta-title\">Looking for Research-Backed Market Opportunities?<\/div>\n<p class=\"wt-cta-copy\">Explore WittyTrades research across market segments.<\/p>\n<p><a class=\"wt-cta-button\" href=\"https:\/\/www.wittytrades.com\/Segments.html\">Explore WittyTrades Research \u2192<\/a><\/aside>\n<h2>Frequently Asked Questions<\/h2>\n<h3 style=\"margin:13px 0 4px;\">Why is MANKIND PHARMA LIMITED share price falling today?<\/h3>\n<p style=\"margin:0;\" class=\"wt-copy\">The downward move appears largely driven by sector-wide weakness in pharmaceutical stocks coupled with routine profit-taking following recent gains. No single major negative corporate catalyst emerged during the session to justify the decline.<\/p>\n<h3 style=\"margin:13px 0 4px;\">How strong is trading participation today?<\/h3>\n<p style=\"margin:0;\" class=\"wt-copy\">Participation is moderate rather than exceptional. Volume is about 0.93x the latest 20-day average.<\/p>\n<div style=\"color:#606b78;border-top:1px solid #e1e7ef;padding-top:13px;margin-top:22px;\"><strong>Disclaimer:<\/strong>Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is informational and educational, not personalised investment advice or a recommendation. Market data may be delayed; verify current information before acting. <\/div>\n<h2>Other Dated Coverage<\/h2>\n<ul class=\"wt-list\">\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-10-01\/\">Why Mankind Pharma Shares Are Down 2.4% Today \u2014 1 October 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-09-30\/\">Why Mankind Pharma Shares Fell 1.6% Today: Sector Trends \u2014 30 September 2026<\/a><\/li>\n<li><a href=\"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-09-29\/\">Mankind Pharma Share Price Rises Today: Why MANKIND Stock is Moving \u2014 29 September 2026<\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/www.wittytrades.com\/market-news\/tag\/mankind\/\">More Mankind Pharma news and dated analysis \u2192<\/a><\/p>\n<p><strong>Article by:<\/strong> <a href=\"https:\/\/www.wittytrades.com\/About_Us.html\">WittyTrades Research Desk<\/a><\/p>\n<\/div>\n<p><script type=\"application\/ld+json\">{\"@context\": \"https:\/\/schema.org\", \"@type\": \"NewsArticle\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-10-05\/#article\", \"mainEntityOfPage\": {\"@type\": \"WebPage\", \"@id\": \"https:\/\/www.wittytrades.com\/market-news\/mankind-share-price-today-2026-10-05\/\"}, \"headline\": \"Why Mankind Pharma Shares Fell 2.21% Today: Sector Weakness & Context | 5 October 2026\", \"description\": \"Mankind Pharma shares dropped 2.21% amid weak pharma sector trends. Read analysis of price action, volume, and recent corporate developments.\", \"datePublished\": \"2026-10-05T08:21:32Z\", \"dateModified\": \"2026-10-05T14:43:53.354897+00:00\", \"author\": {\"@type\": \"Organization\", \"name\": \"WittyTrades Research Desk\", \"url\": \"https:\/\/www.wittytrades.com\/About_Us.html\"}, \"publisher\": {\"@type\": \"Organization\", \"name\": \"WittyTrades\", \"url\": \"https:\/\/www.wittytrades.com\/\"}, \"inLanguage\": \"en-IN\", \"image\": [\"https:\/\/www.wittytrades.com\/market-news\/wp-content\/uploads\/2026\/10\/mankind-company-news-2026-10-05.jpg\"]}<\/script><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mankind Pharma shares dropped 2.21% amid weak pharma sector trends. Read analysis of price action, volume, and recent corporate developments.<\/p>\n","protected":false},"author":1,"featured_media":2595,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"_witty_seo_title":"Why Mankind Pharma Shares Fell 2.21% Today: Sector Weakness & Context | 5 October 2026","_witty_meta_description":"Mankind Pharma shares dropped 2.21% amid weak pharma sector trends. Read analysis of price action, volume, and recent corporate developments.","_witty_primary_phrase":"Mankind Pharma share price 2026-10-05","_witty_reason_label":"sector-aligned profit booking and subdued volume","_witty_reason_confidence":"medium","footnotes":"","_yoast_wpseo_title":"","_yoast_wpseo_metadesc":"","_yoast_wpseo_focuskw":"","rank_math_title":"","rank_math_description":"","rank_math_focus_keyword":"","_aioseop_title":"","_aioseop_description":""},"categories":[3,4],"tags":[32],"class_list":["post-2402","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-movers","category-stocks-in-news","tag-mankind"],"_links":{"self":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/2402","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/comments?post=2402"}],"version-history":[{"count":4,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/2402\/revisions"}],"predecessor-version":[{"id":2597,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/posts\/2402\/revisions\/2597"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media\/2595"}],"wp:attachment":[{"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/media?parent=2402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/categories?post=2402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wittytrades.com\/market-news\/wp-json\/wp\/v2\/tags?post=2402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}